



Advisory 25-09 Olanzapine Training

To: All ALS Agencies

From: Maia Dorsett, MD, PhD, FACEP, FAEMS *M Dorsett*
Associate Regional Medical Director for Education and Quality

Jeremy T. Cushman, MD, MS, EMT-P, FACEP, FAEMS *J T Cushman*
Regional Medical Director

Date: September 2, 2025

Statewide ALS Protocols allow for Olanzapine as a formulary option for ALS Clinicians as part of the Behavioral Emergency and Hospice Protocols. This medication is not required and currently requires Medical Control authorization for administration. To facilitate common understanding for how Olanzapine works, its indications, and ideal patient populations for use, a video training has been developed and is now available:

YouTube: https://youtu.be/1up7iP1v_yc

Prodigy: Agencies using Prodigy can search for the content and assign it directly.

Collaboration: <https://collabornation.net/course/217130> (If you do not already have an account you will be asked to create one but the training is free. If you need to set up an account, use this link: <https://collabornation.net/guest-register/urdpm>)

If an agency would like the MP4 file for upload into their own LMS, they can contact this office.

This training is not required, but rather provided to area agencies to facilitate common understanding of this optional formulary medication.

As a reminder, adding Olanzapine to an agency's formulary requires Agency Medical Director Approval followed by Regional Medical Director Approval as delegated by the REMAC (See Advisory 25-03).

Also please note that Olanzapine requires reconstitution with sterile water as normal saline cannot be used.

With any questions, please do not hesitate to contact this office.

web www.mlrems.org
phone (585) 463-2900
fax (585) 473-3516

office
44 Celebration Drive, Suite 2100
Rochester, NY 14620

mailing
601 Elmwood Avenue, Box 655P
Rochester, NY 14642